BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March

_{//health-fitness.news-articles.net/content/2012/ .. -two-upcoming-investor-conferences-in-march.html}
^{Published in Health and Fitness on Wednesday, February 29th 2012 at 5:13 GMT by Market Wire}  

BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March -- LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about BSTC

LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: [ BSTC ]), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences during the month of March 2012.

• Cowen and Company 32nd Annual Health Care Conference (Boston, MA)
  Wednesday, March 7, 2012 at 10:40 a.m. EST
• ROTH Capital Partners 24th Annual Conference (Laguna Niguel, CA)
  Tuesday, March 13, 2012 at 3:30 p.m. PDT (6:30 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at [ www.biospecifics.com ].

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase 2 and Phase 1 respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals has the development, supply and commercialization rights in Canada, Australia, Brazil and Mexico. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at [ www.biospecifics.com ].

SOURCE BioSpecifics Technologies Corp.

RELATED LINKS
[ http://www.biospecifics.com ]